Three Decades of Research on Plasminogen Activator Inhibitor-1: A Multifaceted Serpin

Paul J. Declerck; Ann Gils

doi:10.1055/s-0033-1334487

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000077.xml

Share / Bookmark

Facebook Linkedin Weibo

Download PDF

Semin Thromb Hemost 2013; 39(04): 356-364
DOI: 10.1055/s-0033-1334487

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Three Decades of Research on Plasminogen Activator Inhibitor-1: A Multifaceted Serpin

Paul J. Declerck

¹Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, Leuven, Belgium

,

Ann Gils

¹Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, Leuven, Belgium

› Author Affiliations

Further Information

Publication History

Publication Date:
16 March 2013 (online)

Abstract
Full Text
References

Buy Article Permissions and Reprints

Abstract

Plasminogen activator inhibitor 1 (PAI-1) is the main inhibitor of tissue-type (t-PA) and urokinase-type (u-PA) plasminogen activator and therefore plays an important role in the plasminogen–plasmin system. PAI-1 is involved in a variety of cardiovascular diseases (mainly through inhibition of t-PA) as well as in cell migration and tumor development (mainly through inhibition of u-PA and interaction with vitronectin). PAI-1 is a unique member of the serpin superfamily, exhibiting particular unique conformational and functional properties. Because of its involvement in various biologic and pathophysiologic processes, PAI-1 has been the subject of many studies, including extensive structural investigations, in vitro cell biologic studies, in vivo animal studies, and epidemiologic studies. The review provides an overview on the current knowledge on PAI-1.

Keywords

plasminogen activator inhibitor 1 - PAI-1 - fibrinolysis - cancer - plasminogen activation - serpin

References
1 Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7 (1) 4-13

Crossref PubMed Search in Google Scholar
2 Medcalf RL. Fibrinolysis, inflammation, and regulation of the plasminogen activating system. J Thromb Haemost 2007; 5 (Suppl. 01) 132-142

Crossref PubMed Search in Google Scholar
3 Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views. J Pathol 2008; 214 (3) 283-293

Crossref PubMed Search in Google Scholar
4 Loskutoff DJ, van Mourik JA, Erickson LA, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci U S A 1983; 80 (10) 2956-2960

Crossref PubMed Search in Google Scholar
5 Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol 1991; 44 (2) 139-143

Crossref PubMed Search in Google Scholar
6 Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990; 68 (1) 1-19

Crossref PubMed Search in Google Scholar
7 Irigoyen JP, Muñoz-Cánoves P, Montero L, Koziczak M, Nagamine Y. The plasminogen activator system: biology and regulation. Cell Mol Life Sci 1999; 56 (1–2) 104-132

Crossref PubMed Search in Google Scholar
8 Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005; 3 (8) 1879-1883

Crossref PubMed Search in Google Scholar
9 Andreasen PA, Riccio A, Welinder KG , et al. Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett 1986; 209 (2) 213-218

Crossref PubMed Search in Google Scholar
10 Ginsburg D, Zeheb R, Yang AY , et al. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 1986; 78 (6) 1673-1680

Crossref PubMed Search in Google Scholar
11 Pannekoek H, Veerman H, Lambers H , et al. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J 1986; 5 (10) 2539-2544

PubMed Search in Google Scholar
12 Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci U S A 1986; 83 (18) 6776-6780

Crossref PubMed Search in Google Scholar
13 Zeheb R, Gelehrter TD. Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1. Gene 1988; 73 (2) 459-468

Crossref PubMed Search in Google Scholar
14 Mimuro J, Sawdey M, Hattori M, Loskutoff DJ. cDNA for bovine type 1 plasminogen activator inhibitor (PAI-1). Nucleic Acids Res 1989; 17 (21) 8872

Crossref PubMed Search in Google Scholar
15 Prendergast GC, Diamond LE, Dahl D, Cole MD. The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1. Mol Cell Biol 1990; 10 (3) 1265-1269

PubMed Search in Google Scholar
16 Hofmann KJ, Mayer EJ, Schultz LD, Socher SH, Reilly CF. Purification and characterization of recombinant rabbit plasminogen activator inhibitor-1 expressed in Saccharomyces cerevisae. Fibrinolysis 1992; 6: 263-272

PubMed Search in Google Scholar
17 Bijnens AP, Knockaert I, Cousin E, Kruithof EK, Declerck PJ. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1. Thromb Haemost 1997; 77 (2) 350-356

PubMed Search in Google Scholar
18 Meissenheimer LM, Verbeke K, Declerck PJ, Gils A. Quantitation of vervet monkey (Chlorocebus aethiops) plasminogen activator inhibitor-1 in plasma and platelets. Thromb Haemost 2006; 95 (5) 902-903

PubMed Search in Google Scholar
19 Xue Y, Björquist P, Inghardt T , et al. Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide. Structure 1998; 6 (5) 627-636

Crossref PubMed Search in Google Scholar
20 Gils A, Pedersen KE, Skottrup P , et al. Biochemical importance of glycosylation of plasminogen activator inhibitor-1. Thromb Haemost 2003; 90 (2) 206-217

PubMed Search in Google Scholar
21 Lawrence D, Strandberg L, Grundström T, Ny T. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells. Eur J Biochem 1989; 186 (3) 523-533

Crossref PubMed Search in Google Scholar
22 Van De Craen B, Scroyen I, Vranckx C , et al. Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1. Thromb Res 2012; 129 (4) e126-e133

Crossref PubMed Search in Google Scholar
23 Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74 (4) 1465-1472

Crossref PubMed Search in Google Scholar
24 Chmielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31 (3) 427-436

Crossref PubMed Search in Google Scholar
25 Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989; 9: 87-115

PubMed Search in Google Scholar
26 Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70 (3) 327-333

Crossref PubMed Search in Google Scholar
27 Declerck PJ, Alessi MC, Verstreken M, Kruithof EK, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71 (1) 220-225

Crossref PubMed Search in Google Scholar
28 Kruithof EK, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70 (5) 1645-1653

PubMed Search in Google Scholar
29 Owensby DA, Morton PA, Wun TC, Schwartz AL. Binding of plasminogen activator inhibitor type-1 to extracellular matrix of Hep G2 cells. Evidence that the binding protein is vitronectin. J Biol Chem 1991; 266 (7) 4334-4340

PubMed Search in Google Scholar
30 Seiffert D, Mimuro J, Schleef RR, Loskutoff DJ. Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin. Cell Differ Dev 1990; 32 (3) 287-292

Crossref PubMed Search in Google Scholar
31 Declerck PJ, De Mol M, Alessi MC , et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988; 263 (30) 15454-15461

PubMed Search in Google Scholar
32 Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260 (21) 11581-11587

PubMed Search in Google Scholar
33 Vaughan DE, Declerck PJ, Van Houtte E, De Mol M, Collen D. Studies of recombinant plasminogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivo. Circ Res 1990; 67 (5) 1281-1286

Crossref PubMed Search in Google Scholar
34 Declerck PJ, De Mol M, Vaughan DE, Collen D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator. J Biol Chem 1992; 267 (17) 11693-11696

PubMed Search in Google Scholar
35 Urano T, Strandberg L, Johansson LBA, Ny T. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. Eur J Biochem 1992; 209 (3) 985-992

Crossref PubMed Search in Google Scholar
36 Munch M, Heegaard CW, Andreasen PA. Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor. Biochim Biophys Acta 1993; 1202 (1) 29-37

Crossref PubMed Search in Google Scholar
37 De Taeye B, Gils A, Declerck PJ. The story of the serpin plasminogen activator inhibitor 1: is there any need for another mutant?. Thromb Haemost 2004; 92 (5) 898-924

PubMed Search in Google Scholar
38 Mottonen J, Strand A, Symersky J , et al. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355 (6357) 270-273

Crossref PubMed Search in Google Scholar
39 Aertgeerts K, De Bondt HL, De Ranter CJ, Declerck PJ. Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. Nat Struct Biol 1995; 2 (10) 891-897

Crossref PubMed Search in Google Scholar
40 Nar H, Bauer M, Stassen JM, Lang D, Gils A, Declerck PJ. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. J Mol Biol 2000; 297 (3) 683-695

Crossref PubMed Search in Google Scholar
41 Sharp AM, Stein PE, Pannu NS , et al. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure 1999; 7 (2) 111-118

Crossref PubMed Search in Google Scholar
42 Jensen JK, Thompson LC, Bucci JC , et al. Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability. J Biol Chem 2011; 286 (34) 29709-29717

Crossref PubMed Search in Google Scholar
43 Lin Z, Jiang L, Yuan C , et al. Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1. J Biol Chem 2011; 286 (9) 7027-7032

Crossref PubMed Search in Google Scholar
44 Lindahl TL, Sigurdardottir O, Wiman B. Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost 1989; 62 (2) 748-751

PubMed Search in Google Scholar
45 Sancho E, Tonge DW, Hockney RC, Booth NA. Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli. Eur J Biochem 1994; 224 (1) 125-134

Crossref PubMed Search in Google Scholar
46 Boncela J, Papiewska I, Fijalkowska I, Walkowiak B, Cierniewski CS. Acute phase protein alpha 1-acid glycoprotein interacts with plasminogen activator inhibitor type 1 and stabilizes its inhibitory activity. J Biol Chem 2001; 276 (38) 35305-35311

Crossref PubMed Search in Google Scholar
47 Berkenpas MB, Lawrence DA, Ginsburg D. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J 1995; 14 (13) 2969-2977

PubMed Search in Google Scholar
48 Vleugels N, Gils A, Mannaerts S, Knockaert I, Declerck PJ. Evaluation of the mechanism of inactivation of plasminogen activator inhibitor-1 by monoclonal antibodies using a stable variant. Fibrinolysis & Proteolysis. 1998; 12: 277-282

Crossref PubMed Search in Google Scholar
49 Dewilde M, Strelkov SV, Rabijns A, Declerck PJ. High quality structure of cleaved PAI-1-stab. J Struct Biol 2009; 165 (2) 126-132

Crossref PubMed Search in Google Scholar
50 Stoop AA, Eldering E, Dafforn TR, Read RJ, Pannekoek H. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries. J Mol Biol 2001; 305 (4) 773-783

Crossref PubMed Search in Google Scholar
51 Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, Wojtowicz A, Selman SH, Jankun J. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Mol Cancer Ther 2003; 2 (1) 19-28

PubMed Search in Google Scholar
52 Ehrlich HJ, Gebbink RK, Keijer J, Linders M, Preissner KT, Pannekoek H. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 1990; 265 (22) 13029-13035

PubMed Search in Google Scholar
53 Keijer J, Linders M, Wegman JJ, Ehrlich HJ, Mertens K, Pannekoek H. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site. Blood 1991; 78 (5) 1254-1261

PubMed Search in Google Scholar
54 Rezaie AR. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 2001; 276 (19) 15567-15570

Crossref PubMed Search in Google Scholar
55 Carrell R, Travis J. Alpha-1-antitrypsin and the serpins - variation and countervariation. Trends Biochem Sci 1985; 10: 20-24

Crossref PubMed Search in Google Scholar
56 Sherman PM, Lawrence DA, Yang AY , et al. Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center. J Biol Chem 1992; 267 (11) 7588-7595

PubMed Search in Google Scholar
57 Sherman PM, Lawrence DA, Verhamme IM, Paielli D, Shore JD, Ginsburg D. Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity. J Biol Chem 1995; 270 (16) 9301-9306

Crossref PubMed Search in Google Scholar
58 Gramling MW, Church FC. Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. Thromb Res 2010; 125 (5) 377-381

Crossref PubMed Search in Google Scholar
59 De Taeye B, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 2005; 5 (2) 149-154

Crossref PubMed Search in Google Scholar
60 Declerck PJ, Juhan-Vague I, Felez J, Wiman B. Pathophysiology of fibrinolysis. J Intern Med 1994; 236 (4) 425-432

Crossref PubMed Search in Google Scholar
61 Juhan-Vague I, Alessi MC, Declerck PJ. Pathophysiology of fibrinolysis. Baillieres Clin Haematol 1995; 8 (2) 329-343

Crossref PubMed Search in Google Scholar
62 Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313 (25) 1557-1563

Crossref PubMed Search in Google Scholar
63 Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342 (8879) 1076-1079

Crossref PubMed Search in Google Scholar
64 Nilsson IM, Ljungnér H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J (Clin Res Ed) 1985; 290 (6480) 1453-1456

Crossref PubMed Search in Google Scholar
65 Wiman B, Ljungberg B, Chmielewska J, Urdén G, Blombäck M, Johnsson H. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med 1985; 105 (2) 265-270

PubMed Search in Google Scholar
66 Schulman S, Wiman B. Duration of Anticoagulation (DURAC) Trial Study Group. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Thromb Haemost 1996; 75 (4) 607-611

PubMed Search in Google Scholar
67 Siemens HJ, Brueckner S, Hagelberg S, Wagner T, Schmucker P. Course of molecular hemostatic markers during and after different surgical procedures. J Clin Anesth 1999; 11 (8) 622-629

Crossref PubMed Search in Google Scholar
68 Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 2007; 97 (3) 336-342

PubMed Search in Google Scholar
69 Sandford RM, Bown MJ, London NJ, Sayers RD. The genetic basis of abdominal aortic aneurysms: a review. Eur J Vasc Endovasc Surg 2007; 33 (4) 381-390

Crossref PubMed Search in Google Scholar
70 Mesters RM, Flörke N, Ostermann H, Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 1996; 75 (6) 902-907

Thieme Connect PubMed Search in Google Scholar
71 Kornelisse RF, Hazelzet JA, Savelkoul HF , et al. The relationship between plasminogen activator inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock. J Infect Dis 1996; 173 (5) 1148-1156

Crossref PubMed Search in Google Scholar
72 Arnman V, Nilsson A, Stemme S, Risberg B, Rymo L. Expression of plasminogen activator inhibitor-1 mRNA in healthy, atherosclerotic and thrombotic human arteries and veins. Thromb Res 1994; 76 (5) 487-499

Crossref PubMed Search in Google Scholar
73 Fay WP, Garg N, Sunkar M. Vascular functions of the plasminogen activation system. Arterioscler Thromb Vasc Biol 2007; 27 (6) 1231-1237

Crossref PubMed Search in Google Scholar
74 Narayanaswamy M, Wright KC, Kandarpa K. Animal models for atherosclerosis, restenosis, and endovascular graft research. J Vasc Interv Radiol 2000; 11 (1) 5-17

Crossref PubMed Search in Google Scholar
75 Schneiderman J, Sawdey MS, Keeton MR , et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A 1992; 89 (15) 6998-7002

Crossref PubMed Search in Google Scholar
76 Robbie LA, Booth NA, Brown AJ, Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol 1996; 16 (4) 539-545

Crossref PubMed Search in Google Scholar
77 Lupu F, Bergonzelli GE, Heim DA , et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13 (7) 1090-1100

Crossref PubMed Search in Google Scholar
78 Prins MH, Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Intern Med 1991; 151 (9) 1721-1731

Crossref PubMed Search in Google Scholar
79 Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94 (9) 2057-2063

Crossref PubMed Search in Google Scholar
80 Thögersen AM, Jansson JH, Boman K , et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98 (21) 2241-2247

Crossref PubMed Search in Google Scholar
81 Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 2001; 21 (4) 611-617

Crossref PubMed Search in Google Scholar
82 Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46 (5) 860-867

Crossref PubMed Search in Google Scholar
83 Nordt TK, Sawa H, Fujii S, Bode C, Sobel BE. Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo. J Mol Cell Cardiol 1998; 30 (8) 1535-1543

Crossref PubMed Search in Google Scholar
84 Schafer K, Müller K, Hecke A , et al. Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 2003; 23 (11) 2097-2103

Crossref PubMed Search in Google Scholar
85 Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268 (15) 10739-10745

PubMed Search in Google Scholar
86 Ringelstein M, Jung A, Berger K , et al. Promotor polymorphisms of plasminogen activator inhibitor-1 and other thrombophilic genotypes in cerebral venous thrombosis: a case-control study in adults. J Neurol 2012; 259 (11) 2287-2292

Crossref PubMed Search in Google Scholar
87 Tsantes AE, Nikolopoulos GK, Bagos PG, Bonovas S, Kopterides P, Vaiopoulos G. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res 2008; 122 (6) 736-742

Crossref PubMed Search in Google Scholar
88 Francis CW. Plasminogen activator inhibitor-1 levels and polymorphisms. Arch Pathol Lab Med 2002; 126 (11) 1401-1404

PubMed Search in Google Scholar
89 Schleef RR, Higgins DL, Pillemer E, Levitt LJ. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 1989; 83 (5) 1747-1752

Crossref PubMed Search in Google Scholar
90 Mehta R, Shapiro AD. Plasminogen activator inhibitor type 1 deficiency. Haemophilia 2008; 14 (6) 1255-1260

Crossref PubMed Search in Google Scholar
91 Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 1997; 90 (1) 204-208

PubMed Search in Google Scholar
92 Zhang ZY, Wang ZY, Dong NZ, Bai X, Zhang W, Ruan CG. A case of deficiency of plasma plasminogen activator inhibitor-1 related to Ala15Thr mutation in its signal peptide. Blood Coagul Fibrinolysis 2005; 16 (1) 79-84

Crossref PubMed Search in Google Scholar
93 Jänicke F, Schmitt M, Pache L , et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993; 24 (3) 195-208

Crossref PubMed Search in Google Scholar
94 Knoop A, Andreasen PA, Andersen JA , et al. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 1998; 77 (6) 932-940

Crossref PubMed Search in Google Scholar
95 Nekarda H, Siewert JR, Schmitt M, Ulm K. Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet 1994; 343 (8889) 117

Crossref PubMed Search in Google Scholar
96 Konecny G, Untch M, Pihan A , et al. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin Cancer Res 2001; 7 (6) 1743-1749

PubMed Search in Google Scholar
97 Kuhn W, Schmalfeldt B, Reuning U , et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 1999; 79 (11-12) 1746-1751

Crossref PubMed Search in Google Scholar
98 Komiyama S, Aoki D, Saitoh E, Komiyama M, Udagawa Y. Biological significance of plasminogen activator inhibitor-1 expression in ovarian clear cell adenocarcinoma. Eur J Gynaecol Oncol 2011; 32 (6) 611-614

PubMed Search in Google Scholar
99 Becker M, Szarvas T, Wittschier M , et al. Prognostic impact of plasminogen activator inhibitor type 1 expression in bladder cancer. Cancer 2010; 116 (19) 4502-4512

Crossref PubMed Search in Google Scholar
100 Gao S, Nielsen BS, Krogdahl A , et al. Epigenetic alterations of the SERPINE1 gene in oral squamous cell carcinomas and normal oral mucosa. Genes Chromosomes Cancer 2010; 49 (6) 526-538

PubMed Search in Google Scholar
101 Halamkova J, Kiss I, Pavlovsky Z , et al. Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients. Hepatogastroenterology 2011; 58 (112) 1918-1925

PubMed Search in Google Scholar
102 Durand MK, Bødker JS, Christensen A , et al. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost 2004; 91 (3) 438-449

PubMed Search in Google Scholar
103 McMahon B, Kwaan HC. The plasminogen activator system and cancer. Pathophysiol Haemost Thromb 2008; 36 (3-4) 184-194

PubMed Search in Google Scholar
104 Binder BR, Mihaly J. The plasminogen activator inhibitor “paradox” in cancer. Immunol Lett 2008; 118 (2) 116-124

Crossref PubMed Search in Google Scholar
105 Kwaan HC, Wang J, Svoboda K, Declerck PJ. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer 2000; 82 (10) 1702-1708

Crossref PubMed Search in Google Scholar
106 Schneider DJ, Chen Y, Sobel BE. The effect of plasminogen activator inhibitor type 1 on apoptosis. Thromb Haemost 2008; 100 (6) 1037-1040

PubMed Search in Google Scholar
107 Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000; 60 (20) 5839-5847

PubMed Search in Google Scholar
108 Brodsky S, Chen J, Lee A, Akassoglou K, Norman J, Goligorsky MS. Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis. Am J Physiol Heart Circ Physiol 2001; 281 (4) H1784-H1792

PubMed Search in Google Scholar
109 Stefansson S, Petitclerc E, Wong MK, McMahon GA, Brooks PC, Lawrence DA. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 2001; 276 (11) 8135-8141

Crossref PubMed Search in Google Scholar
110 Czekay R-P, Loskutoff DJ. Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp Biol Med (Maywood) 2004; 229 (11) 1090-1096

PubMed Search in Google Scholar
111 Kwaan HC, Mazar AP, McMahon BJ. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin Thromb Hemost 2013; 39 (4) 382-391

Thieme Connect PubMed Search in Google Scholar
112 Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3 (1) 35-45

Crossref PubMed Search in Google Scholar
113 Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther 2010; 28 (5) e72-e91

Crossref PubMed Search in Google Scholar
114 Lijnen HR, Juhan-Vague I. The fibrinolytic system and obesity. Thromb Haemost 2002; 88 (5) 882

PubMed Search in Google Scholar
115 Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, Juhan-Vague I. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol 2000; 20 (4) 1150-1154

Crossref PubMed Search in Google Scholar
116 Lijnen HR, Maquoi E, Morange P , et al. Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 2003; 23 (1) 78-84

Crossref PubMed Search in Google Scholar
117 Lijnen HR. Effect of plasminogen activator inhibitor-1 deficiency on nutritionally-induced obesity in mice. Thromb Haemost 2005; 93 (5) 816-819

PubMed Search in Google Scholar
118 Schäfer K, Fujisawa K, Konstantinides S, Loskutoff DJ. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 2001; 15 (10) 1840-1842

PubMed Search in Google Scholar
119 Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006; 26 (10) 2200-2207

Crossref PubMed Search in Google Scholar
120 Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93 (4) 631-640

PubMed Search in Google Scholar
121 Alessi MC, Nicaud V, Scroyen I , et al; DESIR Study Group. Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Results from the D.E.S.I.R. prospective cohort. Thromb Haemost 2011; 106 (3) 416-422

Thieme Connect PubMed Search in Google Scholar
122 Declerck PJ, Gils A, De Taeye B. Use of mouse models to study plasminogen activator inhibitor-1. Methods Enzymol 2011; 499: 77-104

PubMed Search in Google Scholar
123 Dewilde M, Van De Craen B, Compernolle G , et al. Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differences. J Struct Biol 2010; 171 (1) 95-101

Crossref PubMed Search in Google Scholar
124 Gils A, Meissenheimer LM, Compernolle G, Declerck PJ. Species-dependent molecular drug targets in plasminogen activator inhibitor-1 (PAI-1). Thromb Haemost 2009; 102 (3) 609-610

PubMed Search in Google Scholar
125 Matsuo O, Lijnen HR, Ueshima S, Kojima S, Smyth SS. A guide to murine fibrinolytic factor structure, function, assays, and genetic alterations. J Thromb Haemost 2007; 5 (4) 680-689

Crossref PubMed Search in Google Scholar
126 Lijnen HR, van Hoef B, Beelen V, Collen D. Characterization of the murine plasma fibrinolytic system. Eur J Biochem 1994; 224 (3) 863-871

Crossref PubMed Search in Google Scholar
127 Kawasaki T, Dewerchin M, Lijnen HR, Vermylen J, Hoylaerts MF. Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice. Blood 2000; 96 (1) 153-160

PubMed Search in Google Scholar
128 Van De Craen B, Scroyen I, Abdelnabi R , et al. Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo. Thromb Res 2011; 128 (1) 68-76

Crossref PubMed Search in Google Scholar
129 Leik CE, Su EJ, Nambi P, Crandall DL, Lawrence DA. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost 2006; 4 (12) 2710-2715

Crossref PubMed Search in Google Scholar
130 Carmeliet P, Stassen JM, Schoonjans L , et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 1993; 92 (6) 2756-2760

Crossref PubMed Search in Google Scholar
131 Smith LH, Dixon JD, Stringham JR , et al. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 2006; 107 (1) 132-134

Crossref PubMed Search in Google Scholar
132 Farrehi PM, Ozaki CK, Carmeliet P, Fay WP. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 1998; 97 (10) 1002-1008

Crossref PubMed Search in Google Scholar
133 Fay WP, Parker AC, Ansari MN, Zheng X, Ginsburg D. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood 1999; 93 (6) 1825-1830

PubMed Search in Google Scholar
134 Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999; 99 (23) 3050-3055

Crossref PubMed Search in Google Scholar
135 Boulaftali Y, Lamrani L, Rouzaud MC , et al. The mouse dorsal skinfold chamber as a model for the study of thrombolysis by intravital microscopy. Thromb Haemost 2012; 107 (5) 962-971

Thieme Connect PubMed Search in Google Scholar
136 Eitzman DT, Westrick RJ, Nabel EG, Ginsburg D. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood 2000; 95 (2) 577-580

PubMed Search in Google Scholar
137 Matsuno H, Kozawa O, Niwa M , et al. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury. Thromb Haemost 1999; 81 (4) 601-604

PubMed Search in Google Scholar
138 Abderrahmani R, François A, Buard V , et al. PAI-1-dependent endothelial cell death determines severity of radiation-induced intestinal injury. PLoS ONE 2012; 7 (4) e35740

Crossref PubMed Search in Google Scholar
139 Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 2002; 106 (4) 491-496

Crossref PubMed Search in Google Scholar
140 Eren M, Gleaves LA, Atkinson JB, King LE, Declerck PJ, Vaughan DE. Reactive site-dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice. J Thromb Haemost 2007; 5 (7) 1500-1508

Crossref PubMed Search in Google Scholar
141 Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990; 346 (6279) 74-76

Crossref PubMed Search in Google Scholar
142 Eitzman DT, McCoy RD, Zheng X , et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97 (1) 232-237

Crossref PubMed Search in Google Scholar
143 Narasaki R, Xu Z, Liang Z, Fung LC, Donahue D, Castellino FJ, Ploplis VA. The vitronectin-binding domain of plasminogen activator inhibitor-1 plays an important functional role in lipopolysaccharide-induced lethality in mice. J Thromb Haemost 2012; 10: 2618-2621

Crossref PubMed Search in Google Scholar
144 Nagai N, De Mol M, Lijnen HR, Carmeliet P, Collen D. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation 1999; 99 (18) 2440-2444

Crossref PubMed Search in Google Scholar
145 Nagai N, Suzuki Y, Van Hoef B, Lijnen HR, Collen D. Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice. J Thromb Haemost 2005; 3 (7) 1379-1384

Crossref PubMed Search in Google Scholar
146 Nagai N, Van Hoef B, Lijnen HR. Plasminogen activator inhibitor-1 contributes to the deleterious effect of obesity on the outcome of thrombotic ischemic stroke in mice. J Thromb Haemost 2007; 5 (8) 1726-1731

Crossref PubMed Search in Google Scholar
147 Andreasen PA. PAI-1—a potential therapeutic target in cancer. Curr Drug Targets 2007; 8 (9) 1030-1041

Crossref PubMed Search in Google Scholar
148 Soff GA, Sanderowitz J, Gately S , et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 1995; 96 (6) 2593-2600

Crossref PubMed Search in Google Scholar
149 Devy L, Blacher S, Grignet-Debrus C , et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 2002; 16 (2) 147-154

Crossref PubMed Search in Google Scholar
150 Lambert V, Munaut C, Carmeliet P , et al. Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials. Invest Ophthalmol Vis Sci 2003; 44 (6) 2791-2797

Crossref PubMed Search in Google Scholar
151 McMahon GA, Petitclerc E, Stefansson S , et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 2001; 276 (36) 33964-33968

Crossref PubMed Search in Google Scholar
152 Gils A, Declerck PJ. The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb Haemost 2004; 91 (3) 425-437

PubMed Search in Google Scholar
153 Van De Craen B, Declerck PJ, Gils A. The biochemistry, physiology and pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. Thromb Res 2012; 130 (4) 576-585

Crossref PubMed Search in Google Scholar
154 Lee SH, Eren M, Vaughan DE, Schleimer RP, Cho SH. A plasminogen activator inhibitor-1 inhibitor reduces airway remodeling in a murine model of chronic asthma. Am J Respir Cell Mol Biol 2012; 46 (6) 842-846

Crossref PubMed Search in Google Scholar
155 Watanabe R, Nakajima T, Ogawa M , et al. Effects of pharmacological suppression of plasminogen activator inhibitor-1 in myocardial remodeling after ischemia reperfusion injury. Int Heart J 2011; 52 (6) 388-392

Crossref PubMed Search in Google Scholar
156 Tashiro Y, Nishida C, Sato-Kusubata K , et al. Inhibition of PAI-1 induces neutrophil-driven neoangiogenesis and promotes tissue regeneration via production of angiocrine factors in mice. Blood 2012; 119 (26) 6382-6393

Crossref PubMed Search in Google Scholar

Subscribe to RSS

Share / Bookmark

Three Decades of Research on Plasminogen Activator Inhibitor-1: A Multifaceted Serpin

Publication History

Abstract

Keywords

References